MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Alder Biopharmaceuticals Company Profile (NASDAQ:ALDR)

Consensus Ratings for Alder Biopharmaceuticals (NASDAQ:ALDR) (?)
Ratings Breakdown: 2 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $56.00 (45.04% upside)

Analysts' Ratings History for Alder Biopharmaceuticals (NASDAQ:ALDR)
Show:
DateFirmActionRatingPrice TargetActions
8/7/2015Leerink SwannReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/6/2015Leerink SwannBoost Price TargetOutperform$62.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/25/2015Credit SuisseReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/24/2015Credit SuisseInitiated CoverageOutperform$50.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/5/2015Credit SuisseReiterated RatingOutperform$36.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/5/2015Leerink SwannBoost Price TargetOutperform$24.00 -> $31.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/17/2014Credit SuisseBoost Price TargetOutperform$19.00 -> $34.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/2/2014Leerink SwannLower Price Target$26.00 -> $24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/11/2014Sanford C. BernsteinInitiated CoverageOutperform$30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2014Credit SuisseInitiated CoverageOutperform$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2014Wells Fargo & Co.Initiated CoverageOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2014Leerink SwannInitiated CoverageOutperform$26.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 8/31/2013 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha